secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clovis Oncology, Inc. (—)
CIK:        0001466301
Form:       8-K
Filed at:   2022-12-13T23:59:59+00:00
Accession:  0001193125-22-303179
Event type: other_material
Sentiment:  negative
Materiality: 1.00
Item codes: 1.01, 1.03, 2.03, 2.04, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Clovis Oncology files Chapter 11, stalking-horse sale of FAP-2286 to Novartis for $50M upfront
--------------------------------------------------------------------------------

- Filed voluntary Chapter 11 petitions on Dec 11, 2022; will operate as debtor-in-possession.
- Stalking-horse agreement with Novartis to sell FAP-2286 for $50M upfront plus up to $630.75M in milestones.
- Received committed DIP financing of up to $75M from existing noteholders to fund operations during Chapter 11.
- Sale process under Section 363; competing bids solicited; common stock likely to receive no distribution.
- Engaged Perella Weinberg as restructuring investment banker; also seeking sale of other assets.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1466301/000119312522303179/0001193125-22-303179-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1466301/000119312522303179/d386858d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-303179

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer